1. Home
  2. ADXN vs BGLC Comparison

ADXN vs BGLC Comparison

Compare ADXN & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Addex Therapeutics Ltd

ADXN

Addex Therapeutics Ltd

N/A

Current Price

$7.68

Market Cap

10.3M

Sector

Health Care

ML Signal

N/A

Logo BioNexus Gene Lab Corp

BGLC

BioNexus Gene Lab Corp

HOLD

Current Price

$4.12

Market Cap

10.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADXN
BGLC
Founded
2002
2017
Country
Switzerland
Malaysia
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.3M
10.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ADXN
BGLC
Price
$7.68
$4.12
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
7.1K
204.3K
Earning Date
12-04-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$198,824.00
$9,465,006.00
Revenue This Year
$86.57
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
2.21
52 Week Low
$6.51
$2.01
52 Week High
$12.05
$15.60

Technical Indicators

Market Signals
Indicator
ADXN
BGLC
Relative Strength Index (RSI) 45.59 38.44
Support Level $7.48 $3.98
Resistance Level $8.90 $4.23
Average True Range (ATR) 0.48 0.16
MACD 0.04 0.02
Stochastic Oscillator 35.45 30.56

Price Performance

Historical Comparison
ADXN
BGLC

About ADXN Addex Therapeutics Ltd

Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.

About BGLC BioNexus Gene Lab Corp

BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.

Share on Social Networks: